Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer.

Sun, Xianjun; Hou, Wenhou; Liu, Xin; Chai, Jie; Guo, Hongliang; Yu, Jinming.

Afiliação

Sun X; Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academic Sciences, Jinan, Shandong, China.
Hou W; Department of Radiotherapy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academic Sciences, 440 Jiyan Rd., Jinan, 250117, Shandong, China.
Liu X; Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academic Sciences, Jinan, Shandong, China.
Chai J; Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academic Sciences, Jinan, Shandong, China.
Guo H; Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academic Sciences, Jinan, Shandong, China.
Yu J; Department of Radiotherapy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academic Sciences, 440 Jiyan Rd., Jinan, 250117, Shandong, China. yujinmingsdyu@hotmail.com.

Cancer Cell Int ; 20(1): 580, 2020 Dec 03.

Article em En | MEDLINE | ID: mdl-33292253